PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Not-so-tasty: Plastic particles found in food could harm the body

Animal study links nanoplastic consumption with changes in metabolism and liver function

2025-06-01
(Press-News.org) Results from a new animal study suggest that microscopic plastic particles found in food and beverages may affect glucose metabolism and harm organs such as the liver. The findings raise concerns about potential health risks in people and point to the need for more research.

 

As plastic breaks down, it forms micro- (<5 mm) and nanoparticles (<100 nm), which can enter the food chain and end up in seafood and other foods people eat. Studies estimate that a person may ingest around 40,000 to 50,000 microplastic particles a year through food and beverages, with some estimating exposure to be as high as 10 million particles per year.

 

“With the growing concern around micro- and nanoplastic exposure, we wanted to evaluate the impact of this exposure on health,” said Amy Parkhurst, a doctoral candidate in the laboratory of Fawaz George Haj, PhD, at the University of California, Davis. “Our observations that oral ingestion of polystyrene nanoplastics contributes to glucose intolerance and signs of liver injury, confirm and extend what has been recently reported on the effects of nanoplastics in animal models.”

 

Parkhurst, who is also a Clinical and Translational Science Center TL1 research fellow at the University of California, Davis, will present the findings at NUTRITION 2025, the flagship annual meeting of the American Society for Nutrition held May 31–June 3 in Orlando.

 

For the new study, the researchers focused on exposure via oral consumption to mimic nanoparticles found in food and drink. They gave 12-week-old male mice a standard rodent diet with a daily oral dose of polystyrene nanoparticles. Polystyrene is a widely used plastic commonly found in food packaging and products. The researchers chose a daily nanoparticle dose of 60 mg per kilogram of body weight, based on human exposure levels and earlier mouse studies that showed health effects at similar amounts.

 

“We can’t control for all the plastics the mice are exposed to,” said Parkhurst. “However, our study design allowed us to see dose-correlated changes since the nanoplastics-dosed group would have a higher exposure.”

 

Compared to the control group receiving no polystyrene, the mice consuming nanoplastics exhibited systemic glucose intolerance and elevated alanine aminotransferase, which indicates liver injury. In the mice consuming polystyrene, the researchers also observed an increase in gut permeability and elevated levels of endotoxin, which contribute to liver dysfunction.

 

“Our findings warrant further studies to help inform policy around micro and nano plastics,” said Parkhurst. “Robust scientific evidence plays a key role in shaping monitoring efforts and guiding regulations.”

 

The researchers are continuing to study the impact of nanoplastics on other tissues. They would like to perform more studies in rodent models to better understand the tissues and organs affected by nanoplastics and the underlying molecular mechanisms involved.

 

They are also working with Elizabeth Neumann, Ph.D., at the University of California, Davis, to use matrix-assisted laser desorption/ionization mass spectrometry imaging for high-resolution monitoring of nanoplastic bioaccumulation and evaluation of the ensuing tissue-specific metabolic changes.

 

Parkhurst will present this research at 4:48 – 5 p.m. EDT on Sunday, June 1, during the Climate, Health, and Nutrition session in the Orange County Convention Center (abstract; presentation details).

 

Please note that abstracts presented at NUTRITION 2025 were evaluated and selected by a committee of experts but have not generally undergone the same peer review process required for publication in a scientific journal. As such, the findings presented should be considered preliminary until a peer-reviewed publication is available.

 

About NUTRITION 2025

NUTRITION 2025 is the flagship meeting of the American Society for Nutrition and the premier educational event for nutritional professionals around the globe. NUTRITION brings together lab scientists, practicing clinicians, population health researchers and community intervention investigators to identify solutions to today’s greatest nutrition challenges. Our audience also includes rising leaders in the field – undergraduate, graduate and medical students. NUTRITION 2025 will be held May 31– June 3 in Orlando. https://nutrition.org/meeting/ #Nutrition2025

 

About the American Society for Nutrition (ASN)

ASN is the preeminent professional organization for nutrition research scientists and clinicians around the world. Founded in 1928, the society brings together the top nutrition researchers, medical practitioners, policy makers and industry leaders to advance our knowledge and application of nutrition. ASN publishes four peer-reviewed journals and provides education and professional development opportunities to advance nutrition research, practice, and education. Since 2018, the American Society for Nutrition has presented NUTRITION, the leading global annual meeting for nutrition professionals. http://www.nutrition.org

 

Find more news briefs from NUTRITION 2025 at: https://www.eurekalert.org/newsroom/nutrition2025.

 

###

END



ELSE PRESS RELEASES FROM THIS DATE:

For heart health, food quality matters more than cutting carbs or fat

2025-06-01
A new study that followed almost 200,000 people for several decades has found that when it comes to heart health, the quality of food consumed matters as much as following a low-carbohydrate or low-fat diet. The results suggest that choosing healthy, high-quality foods is key to protecting the heart.   In the past two decades, low-carbohydrate and low-fat diets have been promoted for their potential health benefits, such as weight management and improved blood sugar and cholesterol levels. However, the impact of these diets on reducing heart disease risk has remained an ongoing debate.   “We found that what you eat on low-carb or low-fat ...

Study suggests obesity contributes to anxiety and cognitive impairment

2025-06-01
With rates of obesity and anxiety both on the rise—especially among younger Americans—new research suggests that the two conditions may be connected through interactions between the gut and the brain. The study, conducted in mice, links diet-induced obesity with anxiety-like symptoms, alterations in brain signaling and differences in gut microbes that may contribute to impaired brain functioning.   “Several studies have pointed to a link between obesity and anxiety, though it is still unclear whether obesity directly causes anxiety or if the association is influenced by societal pressures,” said Desiree ...

Higher linoleic acid levels linked to lower heart disease and diabetes risk

2025-06-01
New research that used blood markers to measure linoleic acid levels and their relation to cardiometabolic risk adds evidence that this omega-6 fatty acid may help to lower risks for heart disease and type 2 diabetes. The findings challenge claims that seed oils are harmful to cardiometabolic health.   Linoleic acid, which is found in vegetable oils—especially seed oils like soybean and corn oil—and plant foods, is the primary omega-6 fatty acid consumed in the diet.   “There has been increasing ...

Dual-target CAR T cell therapy slows growth of aggressive brain cancer

2025-06-01
CHICAGO – A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell therapy in nearly two-thirds of patients. While survival data is still accumulating, several patients lived 12 months or longer after receiving the investigational therapy, which is notable given the typical survival for this patient population is less than a year.  The findings were presented today at the 2025 American Society of ...

Adding immune checkpoint inhibitor to standard chemotherapy regimen improves outcomes in stage 3 colon cancer, study finds

2025-06-01
BOSTON, June 1, 2025 – Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting. These results stem from the ATOMIC trial, a phase 3 multicenter, randomized, ...

Diet influences survival after stage iii colon cancer, Dana-Farber study finds

2025-06-01
BOSTON, June 1, 2025 – Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis. Engaging in higher levels of physical activity may amplify the positive influence on survival. “One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,” says first author Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber ...

Switch to experimental drug after liquid biopsy detection of breast cancer recurrence improves outcomes

2025-06-01
A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care. The SERENA-6 study, published June 1 in the New England Journal of Medicine and presented concurrently at the annual meeting of the American Society for Clinical Oncology, was conducted at multiple medical centers, principally in Europe, East Asia and the United States, including at Weill ...

Alliance presents results from phase III ATOMIC trial combining atezolizumab with chemotherapy for patients with stage III dMMR colon cancer at ASCO 2025

2025-06-01
June 1, 2025 — The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstrating a statistically ...

Immunotherapy boosts chemotherapy in combating stage 3 colon cancer

2025-06-01
Late-breaking abstract featured at ASCO 2025 ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged. Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific ...

AI deciphers plant DNA: language models set to transform genomics and agriculture

2025-06-01
By leveraging the structural parallels between genomic sequences and natural language, these AI-driven models can decode complex genetic information, offering unprecedented insights into plant biology. This advancement holds promise for accelerating crop improvement, enhancing biodiversity conservation, and bolstering food security in the face of global challenges. Traditionally, plant genomics has grappled with the intricacies of vast and complex datasets, often limited by the specificity of traditional machine learning models and the scarcity of annotated ...

LAST 30 PRESS RELEASES:

First direct observation of the trapped waves that shook the world

New mRNA vaccine is more effective and less costly to develop, Pitt study finds

DNA floating in the air tracks wildlife, viruses — even drugs

Targeting viral enzymes to strengthen brain immunity against HSV-1

Online game, developed at Harvard, proven to reduce partisan animosity

Two plant species invent the same chemically complex and medically interesting substance

Clinical research on psychedelics gets a boost from new study

Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical

African swine fever not recently imported to Europe, has been around for years

APA calls for guardrails, education, to protect adolescent AI users

Wendelstein 7-X sets new performance records in nuclear fusion research

Brain connections at 3 months predict infant emotional development

Listening to life: Speech technology transforms clinical research

ECT sessions shape depression treatment outcomes

Psilocybin enters gastroenterology: First-ever psychedelic study targets treatment-resistant IBS

Renowned psychiatrist illuminates biological roots of mental illness through pioneering research

Ancient collagen can help identify a “wombat the size of a hippo” in the fossil record

Being in nature can help people with chronic back pain manage their condition

Eating rate has sustained effects on energy intake from ultra-processed diets, new study reveals

Rise in expectant mothers in UK with autoimmune diseases since millennium

Majority of riders and drivers in UK 'gig economy' suffer anxiety over ratings and pay, study suggests

Virginia Tech researchers develop recyclable, healable electronics

Cognitive outcomes similar after noncardiac surgery whether perioperative hypotension- or hypertension-avoidance strategies employed

Research spotlight: regional disparities in opioid overdose mortality persist despite national decline

Fighting myeloma with fiber: Plant-based diet offers promise

What makes someone leave a Medicare Advantage plan?

ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

Advancing personalized medicine through pharmacogenomics: Insights from Ochsner Health

Researchers tested an asthma drug for treating alcoholism. It failed except with this group

Set it and forget it: Autonomous structures can be programmed to jump days in advance

[Press-News.org] Not-so-tasty: Plastic particles found in food could harm the body
Animal study links nanoplastic consumption with changes in metabolism and liver function